NRC Health last reported quarterly results on Oct 27, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $38.4 million (+11.0% year over year) and diluted EPS of $0.21. It usually reports 27–34 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 2, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Tuesday. Based on last year's release for the same quarter on Feb 3, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 27–34 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 27, 2026
27 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
38
+11.0%
|
5
|
0.21
+16.7%
|
|
Jul 28, 2026
28 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
35
+4.0%
|
-3
|
-0.15
-1400.0%
|
|
Apr 28, 2026
28 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
35
+3.7%
|
—
|
0.14
-44.0%
|
|
Feb 3, 2026
34 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
35
-4.6%
|
—
|
0.08
-72.5%
|
|
Oct 27, 2025
27 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
35
-3.4%
|
—
|
0.18
-25.0%
|
|
Jul 28, 2025
28 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
34
-2.8%
|
—
|
-0.01
-103.8%
|
|
Apr 28, 2025
28 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
34
-5.0%
|
—
|
0.25
-7.4%
|
|
Jan 27, 2025
27 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
37
-2.9%
|
—
|
0.28
-22.2%
|
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- NRC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lincoln, NE
- SEC filer status
- Accelerated filer
- SEC CIK
- 70487
- Former names
- NATIONAL RESEARCH CORP (until Mar 27, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.